Offer - Urjas Oil for just ₹ 1
Maball 500 Injection 50 Ml is a commercial drug that is prescribed in the form of Injection. Primarily, it is used for the treatment of Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia. Maball 500 Injection 50 Ml also has some secondary and off-label uses. These are listed below.
The correct dosage of Maball 500 Injection 50 Ml depends on the patient's age, gender, and medical history. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
The most common side effects of Maball 500 Injection 50 Ml are Weakness. While these are the most often observed Maball 500 Injection 50 Ml side effects, there are can be others also. These have been listed below. These side effects of Maball 500 Injection 50 Ml are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Maball 500 Injection 50 Ml's effect is Moderate during pregnancy and Severe for lactating mothers. Further, the section on Maball 500 Injection 50 Ml related warnings talks about Maball 500 Injection 50 Ml's effects on the liver, heart and kidney.
Maball 500 Injection 50 Ml is contraindicated in people with pre-existing medical conditions like Hyperkalemia as it can result in adverse effects. The section on Maball 500 Injection 50 Ml contraindications lists all such conditions.
Additionally, Maball 500 Injection 50 Ml may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Maball 500 Injection 50 Ml is considered not safe while driving, and is not addictive.
Maball 500 Injection 50 Ml is used to treat the following -
Other Benefits
If you are suffering from any of the following diseases, you should not take Maball 500 Injection 50 Ml unless your doctor advises you to do so -
Is this Maball 500 Injection 50 Ml habit forming or addictive?
Maball 500 Injection 50 Ml is not addictive in nature.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Rituxan (rituximab)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1106-1109
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 872